Tyrosine and Glutamine-Leucine Are Metabolic Markers of Early-Stage Colorectal Cancers

Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the second leading cause of cancer mortality worldwide.1 Epidemiologic studies2,3 have suggested that metabolic syndrome (MS) increases the risk of CRC. Early screening of CRC effectively increased the 5-year survival rate4 and was of importance for the MS population at high risk of developing CRC.5 Low sensitivity and specificity limit various biomarkers in the early screening of CRC.6 Metabolomics is an emerging tool in systems biology for the discovery of small-molecule metabolic markers.